Transcatheter Aortic Valve Replacement for Failed Small Surgical Bioprostheses
BACKGROUND: Data on the prognostic impact of failed surgical bioprosthetic size following valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) remain limited. OBJECTIVES: This study aimed to assess the impact of failed bioprosthetic size and subsequent prosthesis-patient mismatch (PPM) on midterm outcomes of ViV TAVR. METHODS: We analyzed patients who underwent ViV TAVR for degenerated surgical bioprostheses in the OCEAN-TAVI (Optimized transCathEter vAlvular iNtervention-transcatheter aortic valve implantation) registry. Patients were divided into 2 groups according to the true internal diameter (ID) of bioprostheses: the small bioprosthesis (SB) group (ID ≤20 mm) and the non-small bioprosthesis (NB) group (ID >20 mm). The primary endpoint was a composite of cardiovascular death or heart failure hospitalization at 3 years. Factors associated with severe measured PPM were also examined. RESULTS: Among 367 consecutive patients undergoing ViV TAVR (244 patients in the SB group vs 123 patients in the NB group), 30-day mortality was 0.5%. Severe PPM occurred in 16.9% of the entire cohort and was more prevalent in the SB group (21.3% in the SB group vs 8.3% in the NB group; P = 0.001). The SB group had a higher risk of cardiovascular death or heart failure hospitalization at 3 years (19.1% in the SB group vs 9.8% in the NB group; adjusted HR: 3.48; 95% CI: 1.11-10.87). The SB patients with severe PPM had the highest risk of the primary outcome at 3 years (SB with PPM 39.2% vs NB without PPM 11.0%; adjusted HR: 6.65 [95% CI: 1.95-22.71] compared with the NB group without PPM). Factors associated with severe PPM included larger body surface area, balloon-expandable valve implantation, and true ID ≤20 mm. CONCLUSIONS: ViV TAVR for small surgical bioprostheses was associated with worse clinical outcome, particularly in those with severe PPM. (Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation [OCEAN-TAVI]; UMIN000020423).
Authors
- Masahiko Noguchi (ORCID: https://orcid.org/0000-0003-4501-3449)
- Hiroto Suzuyama (ORCID: https://orcid.org/0000-0001-5881-6166)
- Yasushi Fuku (ORCID: https://orcid.org/0000-0001-6047-8653)
- Hidetaka Nishina (ORCID: https://orcid.org/0000-0001-6326-1468)
- Norihiko Kamioka (ORCID: https://orcid.org/0000-0001-7222-6197)
- Kenji Nishioka
- Kazumasa Yamasaki
- K T Takagi
- Daisuke Hachinohe
- Masahiro Yamawaki
- Gaku Nakazawa
- Yohei Ohno
- Masahiko Asami
- Shinichi Shirai
- Masaki Izumo
- Norio Tada
- Hiroshi Ueno
- Masanori Yamamoto
- Fumiaki Yashima
- Yusuke Watanabe
- Kentaro Hayashida
- Futoshi Yamanaka
- Toru Naganuma
- Toshiaki Otsuka
Institutions
- Tokai University (JP)
- St. Marianna University School of Medicine (JP)
- Keio University (JP)
- Tokoha Gakuen University (JP)
- Kurashiki Central Hospital (JP)
- Sapporo Higashi Tokushukai Hospital (JP)
- New Tokyo Hospital (JP)
- Saiseikai Kumamoto Hospital (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Sapporo Science Center (JP)
- National Cerebral and Cardiovascular Center (JP)
- Tokai University Hospital (JP)
- Saiseikai Utsunomiya hospital (JP)
- Toyohashi Heart Center (JP)
- Mitsui Memorial Hospital (JP)
- Tsukuba Medical Center Hospital (JP)
- Toyama University Hospital (JP)
- Shonan Kamakura General Hospital (JP)
- Saiseikai Yokohama Eastern Hospital (JP)
- Kokura Memorial Hospital (JP)
- Nippon Medical School (JP)
- Teikyo University (JP)
- Kindai University (JP)
Publication Details
- Journal
- JACC Asia
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1016/j.jacasi.2026.01.034
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00